MENU
+Compare
ASND
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$152.43
Change
-$2.15 (-1.39%)
Capitalization
9.13B

ASND Ascendis Pharma A/S Forecast, Technical & Fundamental Analysis

a developer of drug candidates

Industry Biotechnology
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ASND with price predictions
Feb 21, 2025

Momentum Indicator for ASND turns positive, indicating new upward trend

ASND saw its Momentum Indicator move above the 0 level on February 13, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned positive. In of the 89 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ASND just turned positive on February 13, 2025. Looking at past instances where ASND's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

ASND moved above its 50-day moving average on February 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ASND crossed bullishly above the 50-day moving average on February 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The 50-day moving average for ASND moved above the 200-day moving average on February 18, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for ASND moved out of overbought territory on February 21, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ASND broke above its upper Bollinger Band on February 13, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ASND entered a downward trend on February 12, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASND’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (12.496). P/E Ratio (0.000) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). ASND has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (23.310) is also within normal values, averaging (251.218).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

View a ticker or compare two or three
ASND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ASND is expected to report earnings to rise 121.87% to -141 cents per share on May 21

Ascendis Pharma A/S ASND Stock Earnings Reports
Q1'25
Est.
$-1.42
Q4'24
Beat
by $0.65
Q3'24
Missed
by $0.18
Q2'24
Missed
by $0.45
Q1'24
Missed
by $0.82
The last earnings report on February 12 showed earnings per share of -63 cents, beating the estimate of -128 cents. With 444.15K shares outstanding, the current market capitalization sits at 9.13B.
A.I. Advisor
published General Information

General Information

a developer of drug candidates

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
Tuborg Boulevard 12
Phone
+45 70222244
Employees
879
Web
https://www.ascendispharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OBIL50.160.06
+0.11%
US Treasury 12 Month Bill ETF
ECOW20.48-0.09
-0.44%
Pacer Emerging Markets Cash Cows 100 ETF
PPLT88.69-0.93
-1.04%
abrdn Physical Platinum Shares ETF
IPDP19.81-0.39
-1.93%
Dividend Performers ETF
MTUM219.92-5.25
-2.33%
iShares MSCI USA Momentum Factor ETF

ASND and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ASND has been loosely correlated with ORMP. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ASND jumps, then ORMP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASND
1D Price
Change %
ASND100%
-1.39%
ORMP - ASND
37%
Loosely correlated
-3.15%
NUVL - ASND
36%
Loosely correlated
-3.52%
AMRN - ASND
35%
Loosely correlated
-0.82%
AXON - ASND
34%
Loosely correlated
-5.28%
CASI - ASND
33%
Poorly correlated
-0.41%
More